These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38335808)

  • 1. Decoding the dynamics of BCL9 triazole stapled peptide.
    Gaikwad V; Choudhury AR; Chakrabarti R
    Biophys Chem; 2024 Apr; 307():107197. PubMed ID: 38335808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of triazole-stapled BCL9 α-helical peptides to target the β-catenin/B-cell CLL/lymphoma 9 (BCL9) protein-protein interaction.
    Kawamoto SA; Coleska A; Ran X; Yi H; Yang CY; Wang S
    J Med Chem; 2012 Feb; 55(3):1137-46. PubMed ID: 22196480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling.
    Takada K; Zhu D; Bird GH; Sukhdeo K; Zhao JJ; Mani M; Lemieux M; Carrasco DE; Ryan J; Horst D; Fulciniti M; Munshi NC; Xu W; Kung AL; Shivdasani RA; Walensky LD; Carrasco DR
    Sci Transl Med; 2012 Aug; 4(148):148ra117. PubMed ID: 22914623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the interaction of BCL9 with beta-catenin and development of fluorescence polarization and surface plasmon resonance binding assays for this interaction.
    Kawamoto SA; Thompson AD; Coleska A; Nikolovska-Coleska Z; Yi H; Wang S
    Biochemistry; 2009 Oct; 48(40):9534-41. PubMed ID: 19715304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crystal structure of a beta-catenin/BCL9/Tcf4 complex.
    Sampietro J; Dahlberg CL; Cho US; Hinds TR; Kimelman D; Xu W
    Mol Cell; 2006 Oct; 24(2):293-300. PubMed ID: 17052462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of β-catenin/B cell lymphoma 9 protein-protein interaction using α-helix-mimicking sulfono-γ-AApeptide inhibitors.
    Sang P; Zhang M; Shi Y; Li C; Abdulkadir S; Li Q; Ji H; Cai J
    Proc Natl Acad Sci U S A; 2019 May; 116(22):10757-10762. PubMed ID: 31088961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell-type-specific function of BCL9 involves a transcriptional activation domain that synergizes with beta-catenin.
    Sustmann C; Flach H; Ebert H; Eastman Q; Grosschedl R
    Mol Cell Biol; 2008 May; 28(10):3526-37. PubMed ID: 18347063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in β-catenin/BCL9 protein-protein interaction inhibitors.
    Zhang H; Bao Y; Liu C; Li J; Zhu D; Zhang Q
    Future Med Chem; 2021 May; 13(10):927-940. PubMed ID: 33849283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The interactions of Bcl9/Bcl9L with β-catenin and Pygopus promote breast cancer growth, invasion, and metastasis.
    Vafaizadeh V; Buechel D; Rubinstein N; Kalathur RKR; Bazzani L; Saxena M; Valenta T; Hausmann G; Cantù C; Basler K; Christofori G
    Oncogene; 2021 Oct; 40(43):6195-6209. PubMed ID: 34545187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCL9-2 binds Arm/beta-catenin in a Tyr142-independent manner and requires Pygopus for its function in Wg/Wnt signaling.
    Hoffmans R; Basler K
    Mech Dev; 2007 Jan; 124(1):59-67. PubMed ID: 17113272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SOX7 Suppresses Wnt Signaling by Disrupting β-Catenin/BCL9 Interaction.
    Fan R; He H; Yao W; Zhu Y; Zhou X; Gui M; Lu J; Xi H; Deng Z; Fan M
    DNA Cell Biol; 2018 Feb; 37(2):126-132. PubMed ID: 29271667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The function of BCL9 in Wnt/beta-catenin signaling and colorectal cancer cells.
    de la Roche M; Worm J; Bienz M
    BMC Cancer; 2008 Jul; 8():199. PubMed ID: 18627596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Tumor-Suppressor WWOX and HDAC3 Inhibit the Transcriptional Activity of the β-Catenin Coactivator BCL9-2 in Breast Cancer Cells.
    El-Hage P; Petitalot A; Monsoro-Burq AH; Maczkowiak F; Driouch K; Formstecher E; Camonis J; Sabbah M; Bièche I; Lidereau R; Lallemand F
    Mol Cancer Res; 2015 May; 13(5):902-12. PubMed ID: 25678599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cytoplasmic role of Wnt/β-catenin transcriptional cofactors Bcl9, Bcl9l, and Pygopus in tooth enamel formation.
    Cantù C; Pagella P; Shajiei TD; Zimmerli D; Valenta T; Hausmann G; Basler K; Mitsiadis TA
    Sci Signal; 2017 Feb; 10(465):. PubMed ID: 28174279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LATS2 suppresses oncogenic Wnt signaling by disrupting β-catenin/BCL9 interaction.
    Li J; Chen X; Ding X; Cheng Y; Zhao B; Lai ZC; Al Hezaimi K; Hakem R; Guan KL; Wang CY
    Cell Rep; 2013 Dec; 5(6):1650-63. PubMed ID: 24360964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia-inducible factor 1α induces osteo/odontoblast differentiation of human dental pulp stem cells via Wnt/β-catenin transcriptional cofactor BCL9.
    Orikasa S; Kawashima N; Tazawa K; Hashimoto K; Sunada-Nara K; Noda S; Fujii M; Akiyama T; Okiji T
    Sci Rep; 2022 Jan; 12(1):682. PubMed ID: 35027586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pax6-dependent, but β-catenin-independent, function of Bcl9 proteins in mouse lens development.
    Cantù C; Zimmerli D; Hausmann G; Valenta T; Moor A; Aguet M; Basler K
    Genes Dev; 2014 Sep; 28(17):1879-84. PubMed ID: 25184676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BCL9 promotes epithelial mesenchymal transition and invasion in cisplatin resistant NSCLC cells via β-catenin pathway.
    Zhang Y; Zhang Q; Chen H; Wang C
    Life Sci; 2018 Sep; 208():284-294. PubMed ID: 30009824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crystal structure analysis of the PHD domain of the transcription co-activator Pygopus.
    Nakamura Y; Umehara T; Hamana H; Hayashizaki Y; Inoue M; Kigawa T; Shirouzu M; Terada T; Tanaka A; Padmanabhan B; Yokoyama S
    J Mol Biol; 2007 Jun; 370(1):80-92. PubMed ID: 17499269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted disruption of the BCL9/β-catenin interaction by endosomal-escapable nanoparticles functionalized with an E-cadherin-derived peptide.
    Yang G; Zhang J; You W; Zhao X; Hou P; He W; Yan J; Guo H
    Nanotechnology; 2020 Mar; 31(11):115102. PubMed ID: 31751960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.